Tonix Pharmaceuticals Holding Corp Total Liabilities
Tonix Pharmaceuticals Holding Corp total liabilities. Based on the latest financial reports, Tonix Pharmaceuticals Holding Corp (TNXP) has total liabilities worth $32.02 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Tonix Pharmaceuticals Holding Corp asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Tonix Pharmaceuticals Holding Corp (2008–2025)
Total liabilities of Tonix Pharmaceuticals Holding Corp from 2008 to 2025. This chart illustrates how Tonix Pharmaceuticals Holding Corp's total liabilities have evolved over time, based on quarterly financial data. Explore Tonix Pharmaceuticals Holding Corp long-term investment allocation to see how much of total assets are deployed in long-term investments.
Tonix Pharmaceuticals Holding Corp Competitors by Total Liabilities
The table below lists competitors of Tonix Pharmaceuticals Holding Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Talga Group Ltd
F:TGX
|
Germany | €5.87 Million |
|
China Harmony Auto Holding Limited
F:HA5
|
Germany | €6.61 Billion |
|
Aemulus Holdings Bhd
KLSE:0181
|
Malaysia | RM111.97 Million |
|
Eureka Acquisition Corp Unit
NASDAQ:EURKU
|
USA | $1.53 Million |
|
Song Shang Electronics Co Ltd
TWO:6156
|
Taiwan | NT$3.74 Billion |
|
Wilmar Cahaya Indonesia Tbk
JK:CEKA
|
Indonesia | Rp543.59 Billion |
|
Melrose Industries PLC
LSE:MRO
|
UK | GBX4.48 Billion |
|
Hunya Foods Co Ltd
TW:1236
|
Taiwan | NT$963.25 Million |
Liability Composition Analysis (2008–2025)
This chart breaks down Tonix Pharmaceuticals Holding Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see TNXP total asset value.
Liquidity & Leverage Metrics
Tonix Pharmaceuticals Holding Corp Total Liabilities Ratios Explained
Tonix Pharmaceuticals Holding Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tonix Pharmaceuticals Holding Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tonix Pharmaceuticals Holding Corp (2008–2025)
The table below shows the annual total liabilities of Tonix Pharmaceuticals Holding Corp from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $32.02 Million | +37.24% |
| 2024-12-31 | $23.33 Million | -52.32% |
| 2023-12-31 | $48.93 Million | +164.38% |
| 2022-12-31 | $18.51 Million | -16.57% |
| 2021-12-31 | $22.18 Million | +110.56% |
| 2020-12-31 | $10.54 Million | +104.92% |
| 2019-12-31 | $5.14 Million | +93.63% |
| 2018-12-31 | $2.65 Million | +24.18% |
| 2017-12-31 | $2.14 Million | -0.51% |
| 2016-12-31 | $2.15 Million | -68.19% |
| 2015-12-31 | $6.76 Million | +95.83% |
| 2014-12-31 | $3.45 Million | +55.13% |
| 2013-12-31 | $2.22 Million | +91.97% |
| 2012-12-31 | $1.16 Million | -59.77% |
| 2011-12-31 | $2.88 Million | +27841.38% |
| 2010-12-31 | $10.30K | +943.02% |
| 2009-12-31 | $988.00 | -67.07% |
| 2008-12-31 | $3.00K | -- |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and T… Read more